These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 30030331)

  • 1. The Polypill: From Promise to Pragmatism.
    Huffman MD
    PLoS Med; 2015 Aug; 12(8):e1001862. PubMed ID: 26263422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    Bilal U; Cainzos-Achirica M
    N Engl J Med; 2020 Jan; 382(1):94-95. PubMed ID: 31875510
    [No Abstract]   [Full Text] [Related]  

  • 3. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    Brugts JJ
    N Engl J Med; 2020 Jan; 382(1):94. PubMed ID: 31875509
    [No Abstract]   [Full Text] [Related]  

  • 4. Polypill Strategy in Secondary Cardiovascular Prevention.
    Zhang Y; Zhu Z; Gao C
    N Engl J Med; 2022 Dec; 387(23):2197. PubMed ID: 36477041
    [No Abstract]   [Full Text] [Related]  

  • 5. Polypill Strategy in Secondary Cardiovascular Prevention.
    Carney RM; Freedland KE
    N Engl J Med; 2022 Dec; 387(23):2197. PubMed ID: 36477040
    [No Abstract]   [Full Text] [Related]  

  • 6. Polypill Strategy in Secondary Cardiovascular Prevention. Reply.
    Castellano JM; Cordero A; Fuster V
    N Engl J Med; 2022 Dec; 387(23):2197-2198. PubMed ID: 36477042
    [No Abstract]   [Full Text] [Related]  

  • 7. The place of polypill in secondary prevention of stroke.
    Ojji DB; Huffman MD
    Lancet Glob Health; 2023 Oct; 11(10):e1488-e1489. PubMed ID: 37734783
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Prescott DF; Quinn TJ
    Stroke; 2024 Jan; 55(1):e10-e11. PubMed ID: 38134256
    [No Abstract]   [Full Text] [Related]  

  • 9. For
    Rahimi K
    Heart; 2023 Dec; 110(1):1-2. PubMed ID: 38101925
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
    Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
    Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study.
    Cordero A; Dalmau González-Gallarza R; Masana L; Fuster V; Castellano JM; Ruiz Olivar JE; Zsolt I; Sicras-Mainar A; González Juanatey JR
    Clinicoecon Outcomes Res; 2023; 15():559-571. PubMed ID: 37489131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021.
    Li C; Hao J; Zheng Y; Wang C; Yang J; Wang W; Zhang K; Shao C; Hui W; Wang J; Li W; Tang YD
    Diabetol Metab Syndr; 2023 Apr; 15(1):66. PubMed ID: 37005689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
    McMurray JJV; Solomon SD; Docherty KF; Jhund PS
    Eur Heart J; 2021 Mar; 42(13):1199-1202. PubMed ID: 31898736
    [No Abstract]   [Full Text] [Related]  

  • 15. Polypill strategy at the heart of cardiovascular secondary prevention.
    Ibañez B; Castellano JM; Fuster V
    Heart; 2019 Jan; 105(1):9-10. PubMed ID: 30030331
    [No Abstract]   [Full Text] [Related]  

  • 16. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
    Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
    Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.